Literature DB >> 12788904

Antineoplastic ribonucleases selectively kill thyroid carcinoma cells via caspase-mediated induction of apoptosis.

Daniela Spalletti-Cernia1, Rosanna Sorrentino, Sonia Di Gaetano, Angela Arciello, Corrado Garbi, Renata Piccoli, Giuseppe D'Alessio, Giancarlo Vecchio, Paolo Laccetti, Massimo Santoro.   

Abstract

Bovine seminal ribonuclease (BS-RNase), a natural dimeric homolog of bovine pancreatic RNase (RNase A), and HHP2-RNase, an engineered dimeric form of human pancreatic RNase (HP-RNase), are endowed with powerful antitumor effects. Here we show that BS- and HHP2-RNases, but not monomeric RNase A, induce apoptosis of human thyroid carcinoma cell lines. RNase-induced apoptosis was associated with activation of initiation caspase-8 and -9. This was followed by activation of executioner caspase-3, leading to the proteolytic cleavage of poly(ADP-ribose) polymerase. The caspase inhibitor Z-Val-Ala-Asp-(OMe)-fluoromethylketone protected thyroid cancer cells from BS-RNase-induced apoptosis. RNase-triggered apoptosis and caspase activation were accompanied by reduced phosphorylation of Akt/protein kinase B (PKB), a serine-threonine kinase that when phosphorylated is able to deliver survival signals to cancer cells. BS-RNase antitumor effects in nude mice were accompanied by caspase activation and apoptosis. Because of the high selectivity of apoptotic effects for malignant cells, BS- and HHP2-RNase are promising tools for the treatment of aggressive thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12788904     DOI: 10.1210/jc.2002-020373

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis.

Authors:  Rosanna Cozzolino; Gaetano Calì; Maurizio Bifulco; Paolo Laccetti
Journal:  Invest New Drugs       Date:  2009-02-03       Impact factor: 3.850

Review 2.  Antibody-Mediated Enzyme Therapeutics and Applications in Glycogen Storage Diseases.

Authors:  Zhengqiu Zhou; Grant L Austin; Robert Shaffer; Dustin D Armstrong; Matthew S Gentry
Journal:  Trends Mol Med       Date:  2019-09-12       Impact factor: 11.951

3.  Species-specific and collection method-dependent differences in endometrial susceptibility to seminal plasma-induced RNA degradation.

Authors:  Beatriz Fernandez-Fuertes; José María Sánchez; Sandra Bagés-Arnal; Michael McDonald; Marc Yeste; Pat Lonergan
Journal:  Sci Rep       Date:  2019-10-21       Impact factor: 4.379

Review 4.  Biological Activities of Secretory RNases: Focus on Their Oligomerization to Design Antitumor Drugs.

Authors:  Giovanni Gotte; Marta Menegazzi
Journal:  Front Immunol       Date:  2019-11-26       Impact factor: 7.561

5.  Anticancer Activity of Reconstituted Ribonuclease S-Decorated Artificial Viral Capsid.

Authors:  Yingbing Liang; Hiroto Furukawa; Kentarou Sakamoto; Hiroshi Inaba; Kazunori Matsuura
Journal:  Chembiochem       Date:  2022-06-21       Impact factor: 3.461

6.  Highly selective toxic and proapoptotic effects of two dimeric ribonucleases on thyroid cancer cells compared to the effects of doxorubicin.

Authors:  D Spalletti-Cernia; R Sorrentino; S Di Gaetano; R Piccoli; M Santoro; G D'Alessio; P Laccetti; G Vecchio
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

Review 7.  Immune Modulation by Human Secreted RNases at the Extracellular Space.

Authors:  Lu Lu; Jiarui Li; Mohammed Moussaoui; Ester Boix
Journal:  Front Immunol       Date:  2018-05-16       Impact factor: 7.561

8.  The systemic tumor response to RNase A treatment affects the expression of genes involved in maintaining cell malignancy.

Authors:  Nadezhda Mironova; Olga Patutina; Evgenyi Brenner; Alexander Kurilshikov; Valentin Vlassov; Marina Zenkova
Journal:  Oncotarget       Date:  2017-08-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.